Search results
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Journey to the center of the mirth
Politico· 7 days agoLet’s get into it. In today’s edition: → A military who’s who strutted around an airport-adjacent convention center. → First in Playbook: A pandemic vaccine contract inked with AstraZeneca ...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored...
Morningstar· 2 days agoCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC NEWS· 6 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
Raleigh facility plays key role in $245M collaboration - Triangle Business Journal
The Business Journals· 7 days agoA biotech manufacturing facility in Raleigh is a key part of a collaboration between global...
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoKeytruda is the world’s top-selling drug and raked in about $25 billion in revenue for Merck last year. (ben.glickman@wsj.com; @benglickman) 1151 ET – ...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 4 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
